Nureca Q3FY26 Results: Revenue Surges 45.7% YoY to ₹396.40 Crores, Returns to Profitability

Nureca Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, showcasing strong operational performance and a return to profitability. The home healthcare and wellness brand demonstrated significant growth across key financial metrics during the reporting period.

Strong Revenue Growth in Q3FY26

The company's financial performance for Q3FY26 reflected robust business momentum with substantial year-on-year improvements:

Metric	Q3FY26	Q3FY25	Growth (%)
Total Income from Operations	₹396.40 cr	₹272.08 cr	+45.7%
Net Profit Before Tax	₹40.48 cr	(₹38.48 cr)	Positive turnaround
Net Profit After Tax	₹32.31 cr	(₹32.89 cr)	Positive turnaround
Total Comprehensive Income	₹32.31 cr	(₹27.90 cr)	Positive turnaround

The company's total income from operations surged to ₹396.40 crores in Q3FY26, representing a remarkable 45.7% increase compared to ₹272.08 crores in the corresponding quarter of the previous fiscal year.

Profitability Turnaround

Nureca achieved a significant milestone by returning to profitability during the quarter. The company reported a net profit after tax of ₹32.31 crores in Q3FY26, marking a complete turnaround from the net loss of ₹32.89 crores recorded in Q3FY25. This positive shift demonstrates the effectiveness of the company's operational strategies and market positioning.

Nine-Month Performance Overview

The nine-month period ended December 31, 2025, showed sustained growth momentum across the business:

Parameter	Nine Months FY26	Performance
Total Income from Operations	₹1,118.05 cr	Strong revenue base
Net Profit Before Tax	₹89.88 cr	Healthy profitability
Net Profit After Tax	₹69.22 cr	Positive earnings
Earnings Per Share (Basic & Diluted)	₹7.25	Improved shareholder returns

For the nine-month period, total income from operations reached ₹1,118.05 crores, while net profit after tax stood at ₹69.22 crores, indicating consistent performance throughout the fiscal year.

Consolidated vs Standalone Performance

Both standalone and consolidated results showed similar positive trends, with consolidated total income from operations at ₹396.42 crores for Q3FY26 compared to ₹264.63 crores in Q3FY25. The consolidated net profit after tax reached ₹37.34 crores in Q3FY26, against a loss of ₹28.01 crores in the previous year's corresponding quarter.

Earnings Per Share Improvement

The company's earnings per share showed significant improvement, with basic and diluted EPS reaching ₹3.39 for Q3FY26 compared to a loss per share of ₹3.29 in Q3FY25. For the nine-month period, EPS stood at ₹7.25, reflecting the company's enhanced profitability and value creation for shareholders.

The Board of Directors confirmed that the limited review reports do not contain any modified opinion, and the detailed financial results are available on the company's website and stock exchange platforms for comprehensive review by stakeholders.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.81%	+15.58%	+19.07%	+25.64%	-16.05%	-49.38%

Nureca Limited has announced strong financial results for Q3 FY26, demonstrating significant growth across key performance metrics. The digital-first healthcare company, which generates over 90% of its revenue through online sales, has shown remarkable improvement in both revenue and profitability indicators.

Financial Performance Highlights

The company's Q3 FY26 performance showcased substantial growth momentum with revenue from operations reaching ₹396.00 million, representing a robust 46% year-on-year increase from ₹272.00 million in Q3 FY25. The company achieved a remarkable turnaround in profitability with net profit of ₹32.00 million compared to a loss of ₹33.00 million in the previous year.

Metric	Q3 FY26	Q3 FY25	YoY Growth
Revenue from Operations	₹396.00 million	₹272.00 million	+46%
Net Profit	₹32.00 million	₹-33.00 million	Positive turnaround
GMV	₹540.00 million	₹425.00 million	+27%
EBITDA	₹54.00 million (13%)	₹25.40 million (-9%)	+314%

Nine-Month Performance

For the nine-month period ending December 31, 2025, Nureca maintained strong performance indicators across all key metrics.

Parameter	9M FY26 Performance
Revenue from Operations	₹1,126.00 million
GMV	₹1,536.00 million
EBITDA	₹130.00 million (11% margin)
PAT	₹82.00 million (7% margin)

Business Operations and Product Portfolio

Nureca operates as a debt-free, asset-light company with a healthy liquidity position. The company maintains an extensive product portfolio of 285+ active SKUs across multiple healthcare categories including massagers, blood pressure monitors, weighing scales, thermometers, orthopedic products, and respiratory care devices. During Q3 FY26, the company launched 8 new products, continuing its focus on innovation and market expansion.

The company's manufacturing subsidiary, Nureca Technologies Pvt Limited, has received 13 approvals from CDSCO and holds certifications including ISO 9001:2015 and ISO 13485:2016 from Intertek, along with USFDA 510K exempt approval for 7 products. The facility maintains an annual production capacity of 8 lakh units in India.

Digital Platform and Customer Base

Nureca's digital-first approach has resulted in a cumulative customer base of 1.75 crore users by 9M FY26, growing from 1.65 crore in FY25. The company's Dr Trust 360 connected health app has attracted 2.17 million users, offering both free and premium subscription-based health management services.

Regulatory Compliance

The company has updated its registered address details to "Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053" in its investor presentation, ensuring compliance with regulatory requirements under Regulation 30.